L. HERBERT MAURER, M.D.; R. JACKSON FORCIER, M.D.; O. ROSS MCINTYRE, M.D.; KURT BENIRSCHKE, M.D.
In contrast to the conclusion in the recent letter by Pawliger, McLean, and Noyes in the June 1971 ANNALS OF INTERNAL MEDICINE (p. 1012), we cannot conclude that cytosine arabinoside is a relatively safe drug in the treatment of acute leukemia after the first trimester. We have treated a patient with cytosine arabinoside and thioguanine who was pregnant twice during her treatment. Therapeutic abortions were done both times because of the distinct possibility of fetal abnormalities.
The patient, a 24-year-old white married woman, was hospitalized in June 1969 with granulocytopenia, circulating blasts and promyelocytes, lymphadenopathy, splenomegaly, anemia, and thrombocytopenia. She
MAURER LH, FORCIER RJ, MCINTYRE OR, BENIRSCHKE K. Fetal Group C Trisomy After Cytosine Arabinoside and Thioguanine. Ann Intern Med. ;75:809–810. doi: 10.7326/0003-4819-75-5-809_2
Download citation file:
Published: Ann Intern Med. 1971;75(5):809-810.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use